Review article: vascular effects of PPARs in the context of NASH.
Sergi Guixé-MuntetLouise BiquardGyongyi SzaboJean-François DufourFrank TackeSven FrancquePierre-Emmanuel RautouJordi Gracia-SanchoPublished in: Alimentary pharmacology & therapeutics (2022)
PPARs may be attractive for the treatment of NASH due to their liver-specific effects but also because of their efficacy in improving cardiovascular outcomes, which may later impact liver disease. Assessment of cardiovascular disease in the context of NASH trials is, therefore, of the utmost importance, both from a safety and efficacy perspective.